Wodarz, Norbert and Böning, J.
"Ecstasy"-induziertes psychotisches Depersonalisationssyndrom ( = "Ecstasy"-induced psychotic depersonalization syndrome).
Der Nervenarzt 64 (7), pp. 478-480.
The 'designer drug' 3,4-methylenedioxy-metamphetamine (MDMA; 'Ecstasy'), which has become increasingly popular in the past few years, is supposed to induce a feeling of euphoria with amphetamine-like stimulant effects. It was for some time considered harmless, but neurotoxic effects on serotonergic neurons are now well documented. To supplement case reports on different drug-induced psychopathological and somatic complications published in recent literature, the case of a 21-year-old female patient is reported, who exhibited a protracted psychotic depersonalization disorder with suicidal tendency after the first intake of two tablets of "ecstasy". In the course of six months the symptoms remitted only gradually despite administration of a serotonin re-uptake inhibitor, 'flash-backs' occurring repeatedly.
|Institutions:|| Medicine > Lehrstuhl für Psychiatrie und Psychotherapie|
|3,4-Methylenedioxyamphetamine/analogs & derivatives||MESH|
|Combined Modality Therapy||MESH|
|Designer Drugs/adverse effects||MESH|
|Dose-Response Relationship, Drug||MESH|
|Subjects:||600 Technology > 610 Medical sciences Medicine|
|Created at the University of Regensburg:||Unknown|
|Deposited On:||27 Aug 2010 12:20|
|Last Modified:||20 Jul 2011 22:35|